Covered recipient · General Payments record
BRANDON LENOX
Allopathic & Osteopathic Physicians Anesthesiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$14.90
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $14.90 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $14.90 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRANDON LENOX
NPI 1710023098 · CMS profile ID 469116
Allopathic & Osteopathic Physicians / Anesthesiology
MAITLAND, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BRANDON LENOX, NPI 1710023098, CMS profile ID 469116, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $14.90 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $14.90 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848369435 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $13,276,611.80 | 216 |
| PY2024 | Principal investigator | $6,638,229.38 | 94 |
| PY2023 | Recipient | $18,535.52 | 1 |
| PY2023 | Principal investigator | $6,796,584.13 | 63 |
| PY2022 | Recipient | $75,198.00 | 3 |
| PY2022 | Principal investigator | $5,184,921.00 | 42 |
| PY2021 | Recipient | $4,330.51 | 1 |
| PY2021 | Principal investigator | $6,000.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
94 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $927.00 | 12/31/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | M23-515 Ph2 AD Global Study | No dispute reported | 06/30/2026 | 1100764609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $540.00 | 12/20/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018364 |
| Principal investigator 1 | Janssen Research & Development, LLC | $540.00 | 12/20/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018382 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,639.00 | 12/16/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018342 |
| Principal investigator 1 | Janssen Research & Development, LLC | $89,145.00 | 12/13/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018360 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75,113.00 | 12/13/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018390 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 12/09/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1100760537 |
| Principal investigator 1 | Eli Lilly and Company | $213,732.00 | 12/09/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1137360645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,300.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $80,920.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75,140.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,102.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018352 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,650.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,408.00 | 12/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018366 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $78,180.95 | 12/02/2024 | Non-covered Recipient Entity K2 Medical Research - Maitland | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1123477961 |
| Principal investigator 1 | ModernaTX, Inc. | $132,871.07 | 11/27/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147181221 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,681.00 | 11/08/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018362 |
| Principal investigator 1 | Janssen Research & Development, LLC | $760,822.00 | 11/06/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018354 |
| Principal investigator 1 | Janssen Research & Development, LLC | $101,766.00 | 11/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $436,140.00 | 11/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018388 |
| Principal investigator 1 | Eli Lilly and Company | $390.00 | 10/31/2024 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137353334 |
| Principal investigator 1 | Eli Lilly and Company | $28,760.33 | 10/28/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1137360725 |
| Principal investigator 1 | ModernaTX, Inc. | $1,050.00 | 10/21/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147181217 |
| Principal investigator 1 | ModernaTX, Inc. | $8,975.00 | 10/21/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147181219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $109,035.00 | 10/14/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $329,528.00 | 10/14/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018380 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,681.00 | 10/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018372 |
| Principal investigator 1 | ABBVIE INC. | $2,174.00 | 10/03/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1100746704 |
| Principal investigator 1 | ABBVIE INC. | $28,941.00 | 09/03/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1100739388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,643.00 | 08/29/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018336 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/20/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147181215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $540.00 | 08/19/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018332 |
| Principal investigator 1 | ABBVIE INC. | $559.00 | 08/02/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1100734076 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,027.00 | 08/01/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018370 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $89,932.03 | 07/24/2024 | Non-covered Recipient Entity K-2 RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | No dispute reported | 06/30/2026 | 1150029789 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $32,487.68 | 07/24/2024 | Non-covered Recipient Entity K-2 RESEARCH | EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | No dispute reported | 06/30/2026 | 1150029791 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $133,075.00 | 07/19/2024 | Non-covered Recipient Entity K2 Medical Research | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1123477953 |
| Principal investigator 1 | ABBVIE INC. | $3,234.00 | 07/05/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1100727232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,616.00 | 07/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018368 |
| Principal investigator 1 | Eli Lilly and Company | $5,186.95 | 07/01/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137360657 |
| Principal investigator 1 | Janssen Research & Development, LLC | $368.00 | 06/17/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018384 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,739.00 | 06/07/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018356 |
| Principal investigator 1 | ABBVIE INC. | $55,657.00 | 06/05/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100721094 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,310.00 | 05/31/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018334 |
| Principal investigator 1 | ABBVIE INC. | $1,575.00 | 05/30/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100720114 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 05/23/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100719556 |
| Principal investigator 1 | ABBVIE INC. | $17,536.00 | 05/08/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100716538 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,400.00 | 05/03/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018344 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,234.00 | 04/29/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018350 |
| Principal investigator 1 | Eli Lilly and Company | $21,200.00 | 04/15/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1137360651 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 04/15/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018386 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,439.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662712 |
| Principal investigator 1 | ABBVIE INC. | $10,560.00 | 04/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100712132 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,800.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662680 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,600.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662690 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,336.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662694 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,360.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662702 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,200.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662706 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,000.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662710 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,000.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662904 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,216.00 | 04/01/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018374 |
| Principal investigator 1 | ABBVIE INC. | $2,250.00 | 03/28/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100710132 |
| Principal investigator 1 | Bavarian Nordic A/S | $47,537.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662700 |
| Principal investigator 1 | Bavarian Nordic A/S | $13,406.48 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662718 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,650.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662682 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,300.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662692 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,058.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662698 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,080.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662704 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,850.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662708 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,750.00 | 03/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662714 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $451,855.06 | 03/20/2024 | Non-covered Recipient Entity K2 Medical Research - Maitland | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1123477959 |
| Principal investigator 1 | ABBVIE INC. | $8,868.00 | 03/07/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100706090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,729.00 | 03/04/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018378 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,500.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662676 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,755.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662678 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,600.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662684 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,000.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662686 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,060.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662688 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,200.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662716 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,020.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662720 |
| Principal investigator 1 | Bavarian Nordic A/S | $970.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662906 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 02/27/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100705056 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 02/20/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100704192 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,812.00 | 02/08/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1079018376 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 02/01/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH MAITLAND LLC | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease | No dispute reported | 06/30/2026 | 1100701636 |
| Principal investigator 1 | Eli Lilly and Company | $3,910.20 | 01/31/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137360653 |
| Principal investigator 1 | Eli Lilly and Company | $50.40 | 01/29/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1137361529 |
| Principal investigator 1 | Eli Lilly and Company | $12,408.24 | 01/17/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137361329 |
| Principal investigator 1 | Eli Lilly and Company | $931,930.58 | 01/16/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137361527 |
| Principal investigator 1 | Eli Lilly and Company | $328,074.00 | 01/09/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137361327 |
| Principal investigator 1 | Eli Lilly and Company | $243,806.00 | 01/09/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137361525 |
| Principal investigator 1 | Eli Lilly and Company | $15,568.73 | 01/09/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137361531 |
| Principal investigator 1 | Bavarian Nordic A/S | $215.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119662696 |
| Principal investigator 1 | Eli Lilly and Company | $1,368,735.00 | 01/02/2024 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1137361323 |